Member Info for KTRB

Yes you are moaning because you are weak, you know why the SP is dropping because we have a major II selling 3-4% of the company, if it is within your means you should see this as a buying opportunity, because nothing has changed, you will still receive 4 x dividends and the big rises in SP that will attract. Man up and sell a limb or something, opportunity knocks. All my own opinion of course. :)

Err because it's an investment company and the company can invest where they want, err because CF already owns 6.7% of OO with his own money,,,, there is an increasing amount of oxygen thieves on this board.

MOGP is a SPAC and RNS states Raglan Road Capital just bought 5% of the company, that's Open Orphan's CEO investment company, possible the SPAC to reverse into OO a non core business spin off?

RNS states Raglan Road Capital just bought 5% of the company, that's Open Orphan's CEO investment company, possible the SPAC to reverse into OO non core business spin offs?

You wouldn’t want to be out of this overnight now would ya :)

Ah Pat from twitter said Imutex Nasdaq listing is tomorrow,, seems legit

And it can go back again in ten minutes, DYOR look what's happening here

I think we will see a major announcement this week, it’s warming up

https://news.sky.com/story/covid-19-oxford-vaccine-to-be-tested-on-children-as-young-as-six-in-world-first-trial-12216667

We need to keep bumping this to the top of the board, nothing more needs to be said #nobrainer

TILS and Accustem come to mind with this model, but the difference here is that if you sell out post share offer you won't be in the frame for spin out 2, spin out 3, spin out 4 etc. So your core asset (OO) should always be protected in my view anyhow. Winner

It was requested by an investors group on another platform (not my place to name it) and was invite only as there are some real tools on this page nowadays. The questions were submitted by members of the investors group and collated for CF to answer, OO will publish the webinar on the website in the coming days, weeks, months,,, so watch this space.

P.S. It was amazing,,,,, sell me your shares please

Weak people selling, more like, hoover them up - 1 billion company this and 4 x spin off opportunities, Christ its a no brainer easiest decision of my life.

Time for the no news day traders to buy back in now,,, FOMO!!!!

OO is alive again, good luck orphans!

You can come out of your safe spaces now, he’s back and he means business,,,, awesome watch this space MOFO’s

In the UK market sell on news is the mantra, simple as that, it’ll never change

He’s selling it isn’t he, only thing that makes sense for a broker note not to consider the other multiples. I’ll take a buy out for £2.50 a share please, but please do not turn it into an EUA type sale, get it done quick so i can move on.

Leaky leaky, watch this space ;)

If it doesn't drop today for the US market, its definitely another deadline missed along with the accustem Q4 2020 deadline. The BOD need to grip this, nothing worse than missing deadlines set by themselves and broadcasted to the market, reeks of amateur.

It's here, just makes it more official in my book, the worm turns next week chaps, good luck orphans.

The Human Challenge Programme, part of the government’s Vaccine Taskforce, is a partnership between the government, the NHS, academia and the private sector to establish human challenge studies for COVID-19 in the UK.

The programme is funded by Department of Business, Energy, and Industrial Strategy (BEIS) through the Vaccine Taskforce and will be delivered through a partnership between government, hVIVO, Imperial College London, and The Royal Free London NHS Foundation Trust.

This partnership will explore the use of human challenge studies to improve and accelerate the development of vaccines and treatments against COVID-19 and will create a UK-based infrastructure for future human challenge trials supporting the world’s biotech and pharmaceutical industries.

The first stage of this project will explore the feasibility of exposing healthy volunteers to COVID-19. In this initial phase, called the Virus Characterisation Study, the aim will be to discover the smallest amount of virus it takes to cause a person to develop COVID-19. The study will be sponsored by Imperial College London and conducted by hVIVO at the Royal Free Hospital’s specialist research unit in London, under the scrutiny of hVIVO’s highly trained scientists and medics. If the COVID-19 research is approved by regulators, it will begin early next year with results expected by May 2021.

hVIVO will be expanding its Clinical Operations in London to facilitate this work, learn more about openings at www.hvivo.com/careers hVIVO’s, state of the art facility at Queen Mary’s Bioenterprise Centre, London, is booked to maximum capacity until Summer 2021 and will continue to be used to deliver the Company’s traditional challenge study contracts, particularly respiratory syncytial virus (RSV).

Once the characterisation study is completed, this Human Challenge Study model can be utilised to conduct COVID-19 Human Challenge Studies from mid-2021 subject to regulatory approvals.